Hypertension and angiotensin system inhibitors in patients with metastatic renal cell carcinoma

Oncology Reviews

Volumn 10, Issue 2, 2016, Pages 54-59

  Derosa, Lisa ^a   Izzedine, Hassane ^b   Albiges, Laurence ^a   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Angiotensin system inhibitors; Hypertension; Renal cell carcinoma; Renin angiotensin system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERFERON; NEUROHORMONE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TELMISARTAN; TEMSIROLIMUS; THIAZIDE DIURETIC AGENT; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ARTICLE; BLEEDING; CANCER PATIENT; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY CARCINOMA; KIDNEY METASTASIS; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 85002634099     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.4081/oncol.2016.298     Document Type: Article

References (72)

1. Häggström C, Rapp K, Stocks T, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8:e57475.
2. Chow W-H, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-57.
3. Li Y, Li S, Zhu Y, et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens 2014;16:177-85.
4. Qi W-X, He A-N, Shen Z, Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;76:348-57.
5. Soria J-C, Massard C, Izzedine H. From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol 2009;27:1359-61.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
8. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14:552-62.
9. Qi W-X, Lin F, Sun Y-J, et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol 2013;71:431-9.
10. Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013;14:1233-42.
11. Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinibtreated patients for metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol ESMO 2015;26:1128-33.
12. McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2015;21:2471-9.
13. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008;53:376-81.
14. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, doubleblind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49:1287-96.
15. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
16. Escudier B, Porta C, Bono P, et al. Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol Off J Am Soc Clin Oncol 2014 10;32:1412-8.
17. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144-50.
18. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol Off J Am Soc Clin Oncol 2008;26:5422-8.
19. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:2137-43.
20. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23.
21. Midgley R, Kerr D. Bevacizumab - current status and future directions. Ann Oncol Off J Eur Soc Med Oncol ESMO 2005;16:999-1004.
22. An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21.
23. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis Off J Natl Kidney Found 2007;49:186-93.
24. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
25. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008;9:117-23.
26. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:884-96.
27. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol Stockh Swed 2009;48:9-17.
28. Bukowski RM, Yasothan U, Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010;9:17-8.
29. Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Exp Rev Anticancer Ther 2010;10:635-45.
30. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res Off J Am Assoc Cancer Res 2008;14:7272-83.
31. Rini BI, Quinn DI, Baum M, et al. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 2015;10:45-53.
32. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-46.
33. Kappers MHW, Esch JHM van, Sluiter W, et al. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56:675-81.
34. Horowitz JR, Rivard A, Zee R van der, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997;17:2793-800.
35. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054-8.
36. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201.
37. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69 Suppl 3:25-33.
38. Mourad J-J, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol Off J Eur Soc Med Oncol ESMO 2008;19:927-34.
39. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36.
40. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.
41. Tamarat R, Silvestre J-S, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways. Lab Investig J Tech Methods Pathol 2002;82:747-56.
42. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-5.
43. Chiu T, Santiskulvong C, Rozengurt E. ANG II stimulates PKCdependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G1-11.
44. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
45. Kosaka T, Miyajima A, Takayama E, et al. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007;67:41-9.
46. Escobar E, Rodríguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004;2:385-99.
47. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 2005;5:307-23.
48. Hii SI, Nicol DL, Gotley DC, et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
49. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007;67:924-32.
50. Funao K, Matsuyama M, Kawahito Y, et al. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 2008;20:295-300.
51. Dolley-Hitze T, Jouan F, Martin B, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010;103:1698-705.
52. Song T, Choi CH, Kim MK, et al. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP 2016 [Epub ahead of print].
53. Verhoest G, Dolley-Hitze T, Jouan F, et al. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma. Bio Med Res Int 2014;2014:901371.
54. Keizman D, Huang P, Eisenberger MA, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 2011;47:1955-61.
55. Huillard O, Xylinas E, Peyromaure M, et al. Angiotensin system inhibitors in renal cell carcinoma-letter. Clin Cancer Res 2016;22:524.
56. Hamnvik O-PR, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015;121:311-9.
57. Sorich MJ, Kichenadasse G, Rowland A, et al. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: a pooled secondary analysis of clinical trials. Int J Cancer 2016;138:2293-9.
58. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004. Available from: http://www.ncbi.nlm.nih.gov/books/NBK9630/ Accessed: 29 May 2016.
59. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357.
60. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95-7.
61. Bamias A, Lainakis G, Manios E, et al. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors? J Clin Oncol Off J Am Soc Clin Oncol 2009;27:2567-70.
62. Bamias A, Lainakis G, Manios E, et al. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. J Chemother 2009;21:347-50.
63. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. JNCI J Natl Cancer Inst 2010;102:596-604.
64. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15.
65. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
66. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
67. Bhojani N, Jeldres C, Patard J-J, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
68. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-96.
69. Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol Off J Eur Soc Med Oncol ESMO 2007;18:1121-2.
70. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006;48:622-7.
71. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep 2007;9:320-8.
72. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009;35:297-307.